Skip to content
★ Sign in to follow
Xiangyu Medical Co.,Ltd logo

Xiangyu Medical Co.,Ltd Stock: price and insider trades · China

翔宇医疗

CN·Mcap CN¥5.8BHealth Care

No insider purchase over the last 90 days. The latest, by 何永正, was filed 01 Jun 2022.

Xiangyu Medical Co.,Ltd: what insiders have been doing

Headquartered in People's Republic of China, Xiangyu Medical Co.,Ltd belongs to the Health Care sector and traces its origins to 2002. Filings by its managers are published through SSE / SZSE (CSRC). The past year has been quiet: not a single insider filing for Xiangyu Medical Co.,Ltd. The previous disclosure was published on 1 June 2022.

The full history, which starts in 2022, counts 8 purchases against no sales.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Key facts

Headquarters: People's Republic of China · Founded: 2002

Source: Wikidata (CC0).

Insider Decl.
8
Thresholds
n/a
Buy Volume
€2M
8 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 01 Jun 2022 · 1623 days ago · €27k
    +26.4%
    Entry CN¥33.89 · Close at T+365 CN¥42.84

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Xiangyu Medical Co.,Ltd Strong Buy (bullish), based on 1 analysts. Average price target: CN¥53.00.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 18,203 of 26,911 companies
39.9
score / 100
Value
25
Quality
55
FCF yld-1.7%
Earn yld1.3%
EV/EBITDA46.9x
ROE4.0%
Gross mgn67%
Net mgn10%
Debt/EBITDA4.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥36.25
Analyst consensus
1 analysts
Strong buy
CN¥53.00Target CN¥53.00(+46%)CN¥53.00
Income statement
RevenueCN¥767.7M
Gross profitCN¥511.5M67% margin
EBITDACN¥135.8M18% margin
Net incomeCN¥78.2M10.5% margin
Valuation
PER (trailing)68.4x
P/Book2.7x
Beta0.42
Balance sheet & cash
Market capCN¥5.8B
Total debtCN¥574.2M
Free Cash Flow-CN¥97.4M
Debt / Equity27%
Profitability & ownership
ROE4.0%
ROA0.7%
% insiders68.0%
% institutions2.5%
Last declaration on 1 June 2022
Declarations8 total
  • ▲
    董事,核心技术人员Executives
    194,838 CNY7SSE
    6,000 shares1.7% of flowA股XSHGSSE:173000005560699800
    Canonical exit: 30 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    2M CNY8SSE
    52,056 shares13.7% of flowA股XSHGSSE:173000005552153200
    Canonical exit: 25 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    719,100 CNY8SSE
    21,674 shares6.4% of flowA股XSHGSSE:173000005539458980
    Canonical exit: 18 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    581,904 CNY8SSE
    18,000 shares5.2% of flowA股XSHGSSE:173000005537107330
    Canonical exit: 17 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    165,620 CNY7SSE
    5,000 shares1.5% of flowA股XSHGSSE:173000005533907260
    Canonical exit: 16 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    509,460 CNY7SSE
    15,000 shares4.6% of flowA股XSHGSSE:173000005520472450
    Canonical exit: 10 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    4M CNY11SSE
    121,374 shares36.7% of flowA股XSHGSSE:173000005516541340
    Canonical exit: 9 Aug 2022 (T+90)
  • ▲
    董事,核心技术人员Executives
    3M CNY10SSE
    100,500 shares30.0% of flowA股XSHGSSE:173000005514216930
    Canonical exit: 8 Aug 2022 (T+90)

8 of 8 declarations

About Xiangyu Medical Co.,Ltd

翔宇医疗 is a company specializing in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on the development and manufacturing of innovative medical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations